Drug Trial Radar · NCT02351973
Comparison of Single and Combination Diuretics in Low-Renin Hypertension
Last checked: Nov 20, 2026Latest source record: Jul 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
423
Actual
Start
Nov 2009
Primary completion
Jul 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- University of CambridgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Leicester; University of Dundee; University of Glasgow; University of Edinburgh; Imperial College London; Barts & The London NHS Trust; King's College London; University of Birmingham
- First posted
- Jan 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the routine combination of optimal thiazide and K+-sparing diuretic will both increase efficacy of BP reduction and reduce risk of glucose intolerance; and whether K+-sparing diuretics alone may have a neutral or even beneficial effect upon glucose tolerance.
Conditions
- Hypertension
Interventions
HydrochlorthiazideDrug
HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
AmilorideDrug
Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Hydrochlorthiazide and AmilorideDrug
HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label. In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each. In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood glucose measured two hours after oral ingestion of a 75 G glucose drink, following overnight fasting.Time frame: 0, 12 and 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.